Recombinant multi-species NIPAL4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NIPAL4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene likely encodes a membrane receptor. Mutations in this gene have been associated with autosomal recessive congenital ichthyosis. [provided by RefSeq, Feb 2010]
The Alternative Names of target: 9530066K23Rik,ARCI6,ICHTHYIN,ICHYN,Ichthyin,Magnesium transporter NIPA4,NIPA-like protein 4,NIPA4,NIPAL4,Nipal4,Non-imprinted in Prader-Willi/Angelman syndrome region protein 4,RGD1309452,SLC57A6

Target products collectionGo to NIPAL4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP1271-Ag-1/ GM-Tg-hg-IP1271-Ag-2 Human NIPAL4 protein Human
GM-Tg-rg-IP1271-Ag-1/ GM-Tg-rg-IP1271-Ag-2 Rat NIPAL4 protein Rat
GM-Tg-mg-IP1271-Ag-1/ GM-Tg-mg-IP1271-Ag-2 Mouse NIPAL4 protein Mouse
GM-Tg-cynog-IP1271-Ag-1/ GM-Tg-cynog-IP1271-Ag-2 Cynomolgus/Rhesus macaque NIPAL4 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP1271-Ag-1/ GM-Tg-felg-IP1271-Ag-2 Feline NIPAL4 protein Feline
GM-Tg-cang-IP1271-Ag-1/ GM-Tg-cang-IP1271-Ag-2 Canine NIPAL4 protein Canine
GM-Tg-bovg-IP1271-Ag-1/ GM-Tg-bovg-IP1271-Ag-2 Bovine NIPAL4 protein Bovine
GM-Tg-equg-IP1271-Ag-1/ GM-Tg-equg-IP1271-Ag-2 Equine NIPAL4 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP1271-Ag-1/ GM-Tg-hg-IP1271-Ag-2; GM-Tg-rg-IP1271-Ag-1/ GM-Tg-rg-IP1271-Ag-2;
GM-Tg-mg-IP1271-Ag-1/ GM-Tg-mg-IP1271-Ag-2; GM-Tg-cynog-IP1271-Ag-1/ GM-Tg-cynog-IP1271-Ag-2;
GM-Tg-felg-IP1271-Ag-1/ GM-Tg-felg-IP1271-Ag-2; GM-Tg-cang-IP1271-Ag-1/ GM-Tg-cang-IP1271-Ag-2;
GM-Tg-bovg-IP1271-Ag-1/ GM-Tg-bovg-IP1271-Ag-2; GM-Tg-equg-IP1271-Ag-1/ GM-Tg-equg-IP1271-Ag-2
Products Name NIPAL4 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name NIPAL4
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NIPAL4 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.